Columbia, S.C., April 27, 2022 — Healthy Humming, LLC dba SinuSonic is one of eight companies worldwide selected to take part in this distinguished program.
SinuSonic is a multi-patented, revolutionary drug-free, no-mess, two-minute solution to nasal congestion that supercharges the body’s own mucosal clearance ability - providing relief from nasal and sinus congestion. It is compact, easy to use, backed by science and championed by internationally renowned physicians. Most importantly, it's non-addictive and it works.
Rodney Schlosser, MD, medical advisor to SinuSonic says: When using the device, “SinuSonic produces an acoustic vibration that resonates throughout the paranasal sinuses (acoustic vibration or humming is known to increase the production of nasal Nitric Oxide – learn more about the science of SinuSonic here) The acoustic vibration is coupled with positive expiratory pressure as you breathe out. The resulting “flutter” feedback mechanism that the user can hear lets them know that they are properly using the device to get the desired result. Our research shows that over 80% found relief from congestion and 87.5% would recommend the device to a friend or family member.”
The MedTech Accelerator is supported by The Mayo Clinic and Arizona State University Alliance for Health Care. The alliance is developing comprehensive improvements in the science of health care delivery and practice, all toward one goal: continually advancing patient care. Together, the recognized world leader in patient care, education and research, and the nation's No. 1-ranked university for innovation are combining expertise from every corner of health care — doctors to bioengineers to business experts — for an adaptive approach to preparing the next generation of health care pioneers and practitioners in our communities.
David Lewis, CEO of Healthy Humming, LLC says “We are so excited to be part of the Mayo Clinic– ASU MedTech Accelerator program. The assistance from these two prestigious organizations will allow us to learn more about the possible future uses of the SinuSonic and reach a much broader group of people suffering from congestion and allow us to do even more research into improving the daily life of people who have difficulty due to congestive issues daily.”
SinuSonic is available to the public at sinusonic.com
About SinuSonic
Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever nasal congestion relief device to use acoustic vibrations and PEP to provide congestion relief.
For instructional videos, visit sinusonic.com.
Media Contact:
David Lewis
Info@SinuSonic.com (803) 888-6170
Columbia, S.C., May 5, 2022 — SinuSonic is pleased to announce presentation of the results from their study on “Double-blind, sham-controlled trial of a novel device for the treatment of viral upper respiratory tract infection”. This study was an oral podium presentation at the American Rhinological Society Spring meeting in Dallas, TX on April 28-29, 2022. This study showed with the highest level of evidence, a randomized sham controlled study, that regular use of the active SinuSonic device improved nasal congestion.
The prospective study was conducted at the Medical University of South Carolina in 2020-2021. Administration of acoustic vibration and oscillating expiratory positive pressure with SinuSonic has been shown in a prior study to improve nasal congestion and air flow. These interventions are hypothesized to release nasal nitric oxide, a molecule with known antiviral properties. The current study investigated the use of this device to prevent viral upper respiratory infections (URI) and reduce the severity and duration of rhinologic symptoms.
Asymptomatic community dwelling adults were randomized to receive an active or a sham device (3:1). Subjects used the assigned device twice daily beginning at the start of the fall URI season. A validated metric of viral URI symptoms, Total Symptoms Score (TSS), was assessed each day for 8 weeks.
Topline outcomes:
ABOUT NASAL CONGESTION
Chronic nasal congestion impacts roughly 20% of the population and is associated with reduced quality of life, difficulty sleeping, reduced daytime performance, and increased healthcare utilization. It has been estimated that the financial impact of chronic nasal congestion is more than $5 –10 billion annually. A survey conducted by Allergies in Americas found that despite the availability of pharmacologic options, many patients are not satisfied with available options.
ABOUT SINUSONIC
Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever multi-patented (5) nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the U.S. with parts molded in the U.S. and assembled in an FDA-registered facility in Columbia, South Carolina. Since launching in July 2019, SinuSonic is being used in all 50 states. For more information and to view instructional videos, visit sinusonic.com
SinuSonic is available to the public at www.sinusonic.com
Media Contact:
David Lewis
Info@SinuSonic.com (803) 888-6170
See the full article in their online magazine here.
]]>Watch the news interview below:
]]>Many athletes suffer from chronic nasal congestion despite a wide range of pharmacologic solutions. Fortunately, athletic trainers can now recommend SinuSonic - a new, effective hand-held medical device. Athletes who use SinuSonic can expect improved nasal airflow and a reduction of persistent nasal congestion upon initial use. Read more in here.
]]>As many as one in three pregnant women experience persistent nasal congestion in the first, third and sometimes second trimester. SinuSonic, a non-invasive treatment method, uses acoustic vibrations and comfortable pressure to relieve nasal congestion by harnessing the body’s own properties. Learn how women concerned about taking medications to address persistent congestion during their pregnancy may find in SinuSonic an attractive alternative to pharmaceutical interventions. Link to article
]]>SinuSonic, a first of its kind medical device for natural relief of nasal congestion using acoustic humming and oscillating pressure, is celebrating significant sales and research milestones to start 2021. SinuSonic sold more than 10,000 devices globally in 2020, including to happy customers in all 50 states. Additionally, independent researchers with the Medical University of South Carolina are currently studying SinuSonic’s effectiveness in preventing viral upper respiratory infections such as influenza, rhinovirus, and coronaviruses.
“2020 showed us the importance of embracing our health, as well as innovative wellness practices that can become a part of our daily routines,” said SinuSonic inventor and renowned pulmonologist, Dr. Richard K. Bogan. “SinuSonic is helping chronic sinus sufferers bust congestion in a way that’s quick, economic, and holistic. Thousands of users felt the difference for themselves last year and I’m encouraged to reach new corners of the globe in 2021.”
The American-made SinuSonic clears sinuses by combining gentle pressure and vibration to stimulate a user’s nose. The user simply breathes through the nose into the device for two minutes, twice a day. Similar treatments have long been used by pulmonologists to clear the lungs of patients with cystic fibrosis. When applied to the nasal passages, an independent study found more than 80 percent of study participants experienced relief from their chronic sinus congestion. Nearly 90% said they would want their family and friends to try it, too.
“It is so encouraging to know those 10,000 devices sold translates into 10,000 opportunities to enhance the quality of life for chronic congestion sufferers,” said Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and Co-Medical Director at SinuSonic. “Now, as we embark on new research opportunities with SinuSonic in 2021, we are hopeful to be a part of the global conversation about innovative, holistic solutions for viral upper respiratory infections that continue to plague our world.”
Prior SinuSonic research has shown that the acoustic vibrations trigger an increase in nitric oxide (NO) release from the sinuses and nasal passages. NO is a molecule with known antiviral and antibacterial properties. Medical studies unrelated to SinuSonic are already researching the positive effects of externally administering nitric oxide as a potential treatment for upper respiratory infections, including COVID-19. This latest SinuSonic independent study is taking the theory a step further by measuring the body’s ability to prevent infection through harnessing its own natural production of nitric oxide spurred by using the SinuSonic device.
“We are eager to see whether regular use of SinuSonic during cold and flu season can decrease the chance of getting sick from one of these viruses,” said Schlosser.
To learn more about the double-patented device, including the science behind this drug-free, mess-free congestion solution, visit www.sinusonic.com
Dr. Schlosser is the Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC). After graduating from the U.S. Military Academy at West Point and serving for four years on active duty, Dr. Schlosser received his medical degree from the Mayo Clinic. He completed his ENT residency at the University of Virginia and then embarked on a one year fellowship at the University of Pennsylvania devoted to the treatment of advanced sinus disease.
Dr. Schlosser authored a textbook on the management of sinus problems and more than 200 articles and chapters on sinus and nasal topics. He regularly travels the world to speak and teach courses on the latest medical techniques, including endoscopic sinus surgery and computerized image-guided surgery. Dr. Schlosser focuses on difficult adult and pediatric sinus cases involving a host of conditions including nasal obstruction, revision surgeries, sinonasal tumors, encephaloceles/cerebrospinal fluid leaks, severe nasal polyposis, smell and taste disorders, and congenital nasal disorders.
Dr. Soler is an Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina. He attended medical school at Wake Forest University, followed by an ENT residency at Oregon Health and Sciences University. He then completed a fellowship dedicated solely to rhinology and endoscopic sinus surgery at Harvard Medical School. Remaining at Harvard, Dr. Soler devoted an additional year of study, earning a master’s degree in epidemiology.
Dr Soler has published over 150 peer-reviewed articles, most of which focus on outcomes after treatment of diseases of the nose and sinuses. He is a principal investigator on a multi-center NIH study examining outcomes in patients with chronic sinusitis. Dr. Soler’s clinical practice is dedicated primarily to diseases of the nose, sinuses, and skull base. He has particular expertise with difficult-to-manage cases of sinusitis, revision sinus surgery, and surgical treatment of sinonasal tumors.
Though Dr. Schlosser and Dr. Soler are currently employed by the Medical University of South Carolina (MUSC), neither the Medical University of South Carolina, nor any affiliated organizations shall be responsible for information provided herein under any theory of liability or indemnity.
ABOUT SINUSONIC
Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever patented nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the U.S. with parts molded in the U.S. and assembled in an FDA-registered facility in Columbia, South Carolina. Since launching in July 2019, SinuSonic is being used in all 50 states. For more information and to view instructional videos, visit www.sinusonic.com.
Media Contact: The Brandon Agency| Allison Eckley | aeckley@thebrandonagency.com|336-414-4972
]]>We are proud to have Dr. Schlosser sharing the secret of SinuSonic’s success with America as we kick off 2021. Listen below to learn more about how SinuSonic can help put an end to your sinus congestion straight from the doctor, himself!
]]>
Upper respiratory infections are commonly caused by viruses such as influenza, rhinovirus, and coronaviruses. “Nitric oxide has been shown to have anti-viral and anti-bacterial properties and stimulate muco-ciliary clearance, leading to improved congestion and the potential relief of other related symptoms. Our prior research has shown that acoustic vibrations trigger an increase in nitric oxide release from the sinuses and nasal passages,” said Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and co-Medical Director at SinuSonic. “We are eager to see whether regular use of SinuSonic during cold and flu season can decrease the chance of getting sick from one of these viruses.”
Medical studies unrelated to SinuSonic are already researching the positive effects of externally administering nitric oxide as a potential treatment for upper respiratory infections, including COVID-19. This latest SinuSonic independent study will take the theory a step further by measuring the body’s ability to prevent infection through harnessing its own natural production of nitric oxide spurred by using the SinuSonic device. Originally developed to treat chronic nasal congestion without drugs or mess, SinuSonic offers patients the ability to treat moderate to severe nasal congestion by simply breathing into a device, triggering the application of gentle acoustic vibrations and light resistant pressure to provide natural relief.
“A simple and inexpensive way of reducing viral respiratory infections would have tremendous impact for millions of Americans” stated Dr. Zachary Soler, Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina and co-Medical Director of SinuSonic. “Since its inception, SinuSonic has been committed to scientific inquiry. We are eager to bring participants on board into this real-world clinical trial.”
Results from an independent study published in the February 2020 edition of the International Forum of Allergy and Rhinology found more than 80 percent of trial subjects experienced clinically and statistically significant improvements in self-reported nasal congestion scores. Additionally, the SinuSonic device was found to be safe and well tolerated and improves objective AND subjective outcomes in chronic rhinitis. In fact, 87.5% of subjects would recommend SinuSonic to a friend or family member.
To participate in the study, applicants should email Matthew Germroth at germroth@musc.edu
]]>“These conditions are thought to occur due to an inability for patients equalize pressure in their middle ear or sinus cavities. This pressure builds up and causes pain,” explained Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and co-Medical Director at SinuSonic. “Traditional treatments usually require more invasive procedures to alleviate the pressure build up, but SinuSonic may equalize these pressures simply by using acoustic energy and oscillating pressure.”
Originally developed to treat chronic nasal congestion without drugs or mess, SinuSonic offers patients the ability to treat moderate to severe nasal congestion by simply breathing into a device, triggering the application of gentle acoustic vibrations and light resistant pressure to provide natural relief. Results from an independent study published in the February 2020 edition of the International Forum of Allergy and Rhinology found more than 80 percent of trial subjects experienced clinically and statistically significant improvements in self-reported nasal congestion scores. Additionally, the SinuSonic device was found to be safe and well tolerated and improved objective AND subjective outcomes in chronic rhinitis. In fact, 87.5% of subjects would recommend SinuSonic to a friend or family member.
“When you’re bringing a new product to market and potentially expanding the market on its uses of treatment, providing the public with tangible facts, medical study results and validated support from specialty doctors in this arena is critical,” stated Dr. Zachary Soler, Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina and co-Medical Director of SinuSonic. “The results from this study have tremendous potential in providing widespread relief for health issues affecting millions of Americans daily.”
Since launching in July 2019, SinuSonic is being used in all 50 states. To learn more or purchase a SinuSonic device, visit www.SinuSonic.com.
]]>
SinuSonic announced today publication of safety and effectiveness data of the company’s device. Study outcomes were published online in the prestigious International Forum of Allergy and Rhinology (IFAR) — the official journal of the American Rhinologic Society (ARS) and the American Academy of Otolaryngic Allergy (AAOA) - in a paper titled, ‘Safety and Efficacy of a Novel Device Combining Acoustic Vibration with Oscillating Expiratory Pressure for the Treatment of Nasal Congestion’.
A majority of current treatments for nasal congestion and rhinitis are decongestants, antihistamines, and topical steroid nasal sprays, which provide only partial or temporary relief and occasionally with significant side effects. A revolutionary solution for congestion relief, the SinuSonic device enables patients to treat moderate to severe nasal congestion by simply breathing into the device, triggering the application of gentle acoustic vibrations and light resistant pressure to naturally provide relief.
The prospective study, conducted at the Medical University of South Carolina in late 2019, reports clinically and statistically significant improvements in 40 patients with chronic nasal congestion. Patients used the SinuSonic device twice daily for five weeks. Rhinoscopy and patient questionnaires were used to assess safety. Peak nasal inspiratory flow (PNIF), which provides objective measurements, along with clinically recognized qualitative measures were used to assess efficacy. In summary, preliminary data on the use of acoustic vibration and oscillating expiratory pressure for patients with nasal congestion is compelling and promising.
“We were excited to see measurable positive changes in both objective nasal airflow as well as patient reported symptom scores and quality of life,” said Dr. Rodney Schlosser, an internationally known sinus specialist and one of the lead researchers on the study. “Chronic nasal congestion afflicts approximately 20 percent of the population, and often with significant quality of life impacts. Our initial results demonstrate that SinuSonic is a safe and effective treatment alternative to conventional pharmacologic and surgical treatment for these patients.”
Topline outcomes:
This study data will be presented to the American Rhinologic Society during the Combined Otolaryngology Spring Meetings in Atlanta, Georgia on April 22-26, 2020. For more information on SinuSonic, to request a sample, or to schedule a demonstration, please call or email our editorial contacts.
ABOUT NASAL CONGESTION
Chronic nasal congestion impacts roughly 20% of the population and is associated with reduced quality of life, difficulty sleeping, reduced daytime performance, and increased healthcare utilization. It has been estimated that the financial impact of chronic nasal congestion is more than $5 – 10 billion annually. A survey conducted by Allergies in Americas found that despite the availability of pharmacologic options, many patients are not satisfied with available options.
ABOUT SINUSONIC
Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever patent(s) pending nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the U.S. with parts molded in the U.S. and assembled in an FDA-registered facility in Columbia, South Carolina. Since launching in July 2019, SinuSonic is being used in all 50 states. For more information and to view instructional videos, visit www.sinusonic.com.
Though Dr. Schlosser and Dr. Soler are currently employed by the Medical University of South Carolina (MUSC), neither the Medical University of South Carolina, nor any affiliated organizations shall be responsible for information provided herein under any theory of liability or indemnity.
]]>
Columbia, S.C., Nov. 26, 2019 – Healthy Humming, LLC is pleased to announce positive topline data from a prospective outcomes study, which assessed the safety and efficacy of the SinuSonic, a nasal congestion treatment device which combines nasal acoustic vibration with oscillating expiratory pressure.
While chronic nasal congestion impacts millions of Americans each year1, currently available treatments, including pharmacologic and surgical options, demonstrate variable efficacy and side effects. The SinuSonic is the only patents-pending treatment option available today that combines the delivery of acoustic vibrations with the application of oscillating expiratory pressure to relieve nasal congestion. The latest independent study, performed at the Medical University of South Carolina, investigated both the safety and efficacy of SinuSonic for the treatment of nasal congestion.
“We were quite surprised at the effectiveness of the SinuSonic device for patients with nasal congestion. Our data, which will be presented formally early next year, showed significant improvement across all primary and secondary study endpoints after use of SinuSonic, including both objective and patient-reported outcomes,” said principal author, Zachary M. Soler, M.D., M.Sc. of the Medical University of South Carolina.
Topline outcomes from the study included:
“We’re encouraged by the preliminary topline results from this phase I/II clinical trial,” said David Lewis, co-founder of Healthy Humming. “These results should give confidence to patients and physicians that SinuSonic is supported by scientific evidence demonstrating that patients not only feel better but have real changes in nasal airflow after using our device. We’re excited for the full study results to be presented and published next year. In the meantime, we look forward to spreading the word that SinuSonic is a great option for millions of Americans suffering from nasal congestion.”
This latest study aimed to test the safety and effectiveness of the SinuSonic device on adults with moderate to severe nasal congestion. The study was performed at the Sinus Center of the Medical University of South Carolina. While final results will be formally presented in early 2020, more information about the study can be found posted on the U.S. National Library of Medicine's clinical study resource center by visiting ClinicalTrials.gov.
Disclaimers
Though Dr. Soler is currently employed by the Medical University of South Carolina (MUSC), neither the Medical University of South Carolina, nor any affiliated organizations shall be responsible for information provided herein under any theory of liability or indemnity.
1Stewart M, Ferguson B, Fromer L. Epidemiology and burden of nasal congestion. Int J Gen Med 2010;3:37-45
2 Peak Nasal Inspiratory Flow is an objective measure that measures nasal airflow during inspiration and supplements standard patient reported outcome measures.
]]>Columbia, S.C., July 16, 2019 — Affecting up to 20-percent of the population, nasal congestion is a common phenomenon that plagues millions everyday and is estimated to have a financial impact costing Americans more than $6 billion, annually, in overall health expenditures, productivity and lost wages. Nasal congestion, sinus congestion, and ‘stuffiness’ has historically been an ailment that most sufferers simply cannot find a solution for long-term relief. Doctors and researchers in South Carolina have teamed up to create a new product that provides the sound solution for congestion relief, the SinuSonic.
Richard K. Bogan, MD, and David Lewis, longtime South Carolina-based partners in sleep-science health ventures since 1994, invented the SinuSonic in 2017. The idea for SinuSonic started after Dr. Bogan’s realization that humming positively impacted his own nasal congestion After exhaustive research, initial clinical trials, prototype development and product design – including work with Clemson University’s Biomedical Engineering Department and with seven seniors’ capstone projects in the Biomedical and Electrical Engineering Departments at University of South Carolina – the SinuSonic is ready for the market and now available for purchase on www.SinuSonic.com.
Healthy Humming, LLC., the parent company of the SinuSonic, is a SCRA (South Carolina Research Authority) Client Company of its entrepreneurial program, “SC Launch.” Client Companies receive mentoring and support services and may also be eligible for grants, matching funds and investments. Chartered in 1983 by the State of South Carolina as a public, non-profit corporation, SCRA fosters South Carolina's Innovation Economy by supporting entrepreneurs, enabling academic research and its commercialization, and connecting industry to innovators.
This patents-pending device utilizes the application of gentle acoustic vibrations and light resistant pressure to naturally help provide congestion relief. In an easy-to-use, disposable handheld device, SinuSonic provides an option for those suffering from nasal and/or sinus congestion and stuffiness to finally find relief without the need for prescription and over-the-counter drugs, messy and uncomfortable nasal irrigators or rinses, or costly surgeries.
“Working with some of the top ENT doctors in the country, including here in South Carolina, we developed the SinuSonic on the idea that a better solution should be available for everyone who suffers from congestion,“ said David Lewis, co- founder and inventor of SinuSonic. “Many have tried everything available and just can’t get relief. And through our early clinical studies, seeing the faces of our trial subjects and the immediate sense of relief they express has been very exciting. We look forward to sharing SinuSonic with all who suffer from nasal congestion in the coming months.”
With an MSRP at $49.95, SinuSonic can be purchased online at www.SinuSonic.com. Each device is easy to use and lasts for up to 60 days or 500 minutes. Users simply hold the device’s nasal mask to their nose and press the device’s trigger button to activate a gentle acoustic vibration. By breathing in and out through the device, users experience light resistance and an oscillating ‘flutter’ pressure as they exhale. The simple combination of sound and pressure has been shown to relieve nasal congestion.
The SinuSonic’s first study examined patients with chronic nasal congestion and demonstrated a clinical improvement in nasal congestion and airway conductivity. Currently a larger clinical trial is underway at the Medical University of South Carolina in Charleston, whose Ear, Nose and Throat clinic is nationally ranked by the U.S. News & World Report’s Best Hospitals Rankings.
For more information, request a sample, or to schedule a demo meeting, please call or email our editorial contacts.
ABOUT SINUSONIC
Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the USA with parts molded in the USA and assembled in an FDA-registered facility in Columbia, South Carolina. For more information and see instructional videos, visit www.sinusonic.com.
]]>